Business Wire

Dabigatran’s safety and efficacy established for management of VTE in children

Share

Boehringer Ingelheim today announced results from two paediatric studies of dabigatran etexilate, which were presented at the International Society on Thrombosis and Haemostasis (ISTH) 2019 Congress in Melbourne, Australia.1,2

The data showed dabigatran to be as effective and have a comparable safety profile to the current standard of care (SOC) for the treatment of acute venous thromboembolism (VTE) in children.1 A favourable safety profile for dabigatran was also established in a second study, the first of its kind to assess direct oral anticoagulant (DOAC) for the prevention of recurrent VTE in children with persistent VTE risk factors.2

Current SOC for treatment and prevention of recurrent VTE in children have several limitations, including the need for frequent monitoring and non-oral means of administration.2 The aim of these new dabigatran studies was to provide additional insight and knowledge on anticoagulation in paediatric patients with VTE, or at risk of recurrent VTE.

“The diagnosis and incidence of VTE has risen dramatically over the years, and childhood VTE is associated with considerable morbidity. Although treatments are currently available to help manage VTE, there is still a need for effective, safe and more convenient options that have been investigated in children. We therefore wanted to assess if dabigatran’s established safety and efficacy, in treating adults with VTE, also translated through to paediatric patients,” said Prof. Dr Martina Brückmann, Global Head of Clinical Development Cardiovascular, Cardiometabolic Medicine, Boehringer Ingelheim. “It is therefore encouraging that these studies suggest a comparable safety profile and efficacy for dabigatran for the potential treatment and prevention of recurrent VTE in children.”

Pradaxa is not approved in any country for paediatric patients with VTE. The studies form part of the ongoing commitment from Boehringer Ingelheim to expanding scientific knowledge of thrombosis care. The safety and efficacy profile of dabigatran in adults has been proven and well-documented in the extensive RE-VOLUTION® clinical trial programme.3-25

About the DIVERSITY study, Ablisetti M et al

Open-label, randomised, multicentre, Phase IIb/III trial evaluated the efficacy and safety of dabigatran vs SOC (low molecular weight heparin or vitamin K antagonist) in children aged from birth to <18 years old with acute VTE requiring anticoagulation therapy for 3 months.1

The combined efficacy endpoint was the proportion of children with recurrent VTE, VTE-related death, and thrombus resolution. The secondary endpoints included safety as determined by bleeding events, and pharmacokinetic/pharmacodynamic relationships.1

The results from the DIVERSITY trial demonstrated that dabigatran was non-inferior to SOC for paediatric patients at high risk of VTE, with comparable bleeding rates.1

About the secondary VTE prevention study, Brandao L et al.

Open-label, single-arm, prospective cohort, Phase III trial is the first study of its kind to describe outcomes in children treated with a direct oral anticoagulant for secondary VTE prevention. In the study, approximately 200 children received dabigatran for up to 12 months. The primary endpoints for this study included VTE recurrence, bleeding events, and mortality at 6 and 12 months.2

The study showed a low overall frequency of recurrent VTEs and any major bleeding events.2 Based on these results, the authors concluded that this trial showed “favourable safety results” with dabigatran in children with VTE and persistent thrombosis risk factors.2

Please click on the following link for ‘Notes to Editors’ and ‘References’: http://www.boehringer-ingelheim.com/press-release/dabigatrans-safety-efficacy-confirmed-vte-children

Intended audiences:

This press release is issued from our Corporate Headquarters in Ingelheim, Germany and is intended to provide information about our global business. It is directed to the international audience outside Germany. Please be aware that information relating to the approval status and labels of approved products may vary from country to country, and a country-specific press release on this topic may have been issued in the countries where we do business.

Contact information

Boehringer Ingelheim
Corporate Communications
Media + PR
Meike Bausinger
Phone: +49 6132 77 182085
Mobile: +49 151 44061760
Fax: +49 6132 77 6601
Email: press@boehringer-ingelheim.com

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Vertex Confirms Wales Offer Accepted for Access to All Licensed Cystic Fibrosis Medicines13.11.2019 11:29:00 CETPress release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today confirms that NHS Wales has accepted an offer for all currently licensed Vertex cystic fibrosis (CF) medicines and any future indications of these medicines under the same terms as the recently announced agreement with NHS England. This means that once the contract is finalized, patients with CF in Wales ages 2 years and older who have two copies of the F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene can access ORKAMBI ® (lumacaftor/ivacaftor) and CF patients ages 12 years and older who either have two copies of the F508del mutation or one copy of the F508del mutation and a copy of one of the other 14 licensed mutations can access SYMKEVI® (tezacaftor/ivacaftor) in combination with ivacaftor in the coming weeks. The agreement also offers expanded access to KALYDECO ® (ivacaftor) to include those patients ages 12 months and older who have one of the nine licensed gating mutations. “Today’s a

Software Testing and Digital Transformation Partners Recognized at 2019 Tricentis Partner Awards13.11.2019 11:00:00 CETPress release

Tricentis, the cloud’s #1 Continuous Testing Platform, today recognized top-performing partners from around the world during Tricentis Accelerate 2019 in Vienna, Austria. In its 5th year, the Tricentis Partner Awards recognize organizations for accelerating digital transformation across the enterprise. Award winners were selected from more than 300 different partners worldwide based on their collaboration with Tricentis, customers, and their advocacy for Tricentis’ automation methodologies. “Tricentis partners are leading the way for organizations to innovate faster, reduce business risk, and optimize cost,” said Alan Ota, Senior Vice President of Strategic Alliances, Tricentis. “Our partners are instrumental to our business and are focused on delivering the best in-class testing solutions to our joint customers. Our tremendous growth would not be possible without our global partners. We’re proud to acknowledge the achievements made by our partners in 2019 and look forward to continuin

Applicaster Appoints Jason Johns as Vice President of Sales, EMEA and APAC13.11.2019 10:00:00 CETPress release

Applicaster, the company simplifying the lifecycle management of direct-to-consumer media applications, today announced the appointment of Jason Johns as Vice President of Sales, EMEA and APAC. In his role, Johns will oversee Applicaster’s EMEA and APAC commercial and go-to-market strategies. “There is an incredible amount of opportunity in the media app market,” said Johns. “Because of our ability to enable frictionless growth for customers, we’re very well positioned to take advantage of this opportunity. Beyond the market opportunity, I was attracted to Applicaster because of the company’s customer-first culture plus its ability and desire to drive value lead engagements. Few businesses buy technology without a clear understanding of the business case and full transparency of the cost-of-ownership around their technology investments - Applicaster understands this and provides flexible commercial models that scale and can easily be upgraded and expanded as business requirements evolv

Clovis Oncology Announces Reimbursement for Rubraca® (rucaparib) Tablets for Women with Relapsed Ovarian Cancer in Italy13.11.2019 09:00:00 CETPress release

Clovis Oncology, Inc. (NASDAQ: CLVS) today announced that the Italian Medicines Agency (AIFA) has approved rucaparib for reimbursement in Italy. Rucaparib will soon be available as an option for monotherapy maintenance treatment for adults with relapsed, platinum-sensitive high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer that has responded to platinum-based chemotherapy.3 Rucaparib is indicated for eligible patients regardless of BRCA status, which means it can be prescribed for women who harbor a BRCA mutation or who are BRCA wild-type.3 “We very much welcome the arrival of the PARP inhibitor rucaparib, which offers a new treatment option after surgery and two lines of chemotherapy to all eligible women affected by relapsed ovarian cancer,” declared Nicoletta Cerana, National President of Acto Onlus, the number one Italian network of patient associations involved in the fight against ovarian cancer and gynecological tumors. “Ovarian cancer is a highly lethal

Traxens Presents Solutions for Port Industry at Smart Ports Barcelona13.11.2019 07:30:00 CETPress release

Traxens, a company providing high-value data and services for the supply chain industry, announces today that it will present its smart asset tracking solutions at the Smart Ports Barcelona event, Smart Ports, Piers of the Future, November 19 to 21. Its tailored Industrial Internet of Things (IIoT) solutions are specifically designed to meet the needs of the port industry by providing near real-time insight into the end-to-end global supply chain. Traxens’ solution provides comprehensive, precise and timely data on cargo, through tracking logistic assets in transit anywhere in the world. Traxens’ patented breakthrough Internet of Things (IoT) technology brings improved efficiency and security, greater transparency and enhanced asset utilization whilst opening up new opportunities for all actors involved in the global supply chain. With Traxens’ solutions, ports can improve their efficiency and the interoperability of the systems with a trusted third party. For example, the Cargo Commun

PMC Group Announces Agreement to Acquire Lanxess’ Organotin Specialties Business13.11.2019 06:30:00 CETPress release

PMC Group N.A., Inc. ("PMC") and Lanxess Organometallics GmbH are pleased to announce that the parties have reached an agreement whereby PMC’s European subsidiary will acquire the organotin specialties product line (the “Business”) from Lanxess. The transaction is scheduled to close by year end, subject to customary closing conditions. The Business includes Lanxess’ global organotin catalyst, organotin specialties and intermediates product lines. The transaction includes a toll manufacturing agreement under which Lanxess will continue to manufacture certain products post-closing for PMC at its Bergkamen, Germany organometallics manufacturing facility. Mr. Debtosh Chakrabarti, President of PMC said, “This acquisition represents PMC’s continuing commitment to the organotin industry and is synergistic to our existing organometallics and catalyst businesses. We believe that the customer base of the Business as well as all of PMC’s customers will benefit significantly from combining the tec